BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioNews
Biotechnology, Pharmaceutical and Life Science News
search help

Search Results

Documents 1-14 out of 14 found
  Current Search:  coronary: 518, restenosis: 14     

HTML
100%
Addition of Cilostazol to Aspirin and a Thienopyridine for Prevention of Restenosis After Coronary Artery Sten
The purpose of this study is to evaluate the effect of adding cilostazol to dual antiplatelet therapy (aspirin and thienopyridine) on rates of restenosis after coronary artery stenting.

A meta-analysis is conducted of randomized, controlled trials comparing 3...

Journal of Clinical Pharmacology:  Mar 17 2010 10:28PM
Matching: coronary restenosis
Find similar documents
HTML
62%
Cypher, Taxus Fare Equally Well in Treating SES Restenosis
When restenosis develops in a sirolimus-eluting stent (SES), intervention with either another SES or a paclitaxel-eluting stent (PES) provides similar efficacy and safety, according to a study published online March 10, 2010, ahead of print in the Journal of...
TCTMD.com:  Mar 12 2010 2:43AM
Matching: restenosis
Find similar documents
HTML
62%
Restenosis rates following vertebral artery origin stenting: does stent type make a difference? March 01, 2010
_ Restenosis rates following vertebral artery origin stenting: does stent type make a difference?

March 01, 2010?

Journal of Invasive Cardiology:  Mar 11 2010 6:07AM
Matching: restenosis
Find similar documents
HTML
62%
Meta-analysis: DES Superior to BMS in Saphenous Vein Grafts
Implanting drug-eluting stents (DES) in diseased saphenous vein grafts (SVG) prevents restenosis and the need for repeat revascularization more effectively than using bare metal stents (BMS), according a large meta-analysis published online February 22, 2010,...
TCTMD.com:  Mar 4 2010 4:18AM
Matching: restenosis
Find similar documents
HTML
100%
Addition of Cilostazol to Aspirin and a Thienopyridine for Prevention of Restenosis After Coronary Artery Stenting: A Meta-Analysis
Jennings DL et al.

Addition of Cilostazol to Aspirin and a Thienopyridine for Prevention of Restenosis After Coronary Artery Stenting: A Meta-Analysis.

MDLinx:  Feb 26 2010 10:24AM
Matching: coronary restenosis
Find similar documents
HTML
100%
Multidetector Computed Tomography Coronary Angiography for the Assessment of Coronary In-Stent Restenosis
Andreini D et al.

The data from 24 studies are reported, 6 performed with oldgeneration scanners and 18 performed with 64slice MDCT or dualsource MDCT.

With oldgeneration MDCT, up to 18% of coronary stents were missed, the rate of nonevaluable stents ranged...

MDLinx:  Feb 26 2010 10:24AM
Matching: coronary restenosis
Find similar documents
HTML
100%
Evaluation of Coronary Artery In-stent Restenosis by 64-Section Computed Tomography: Factors Affecting Assessment and Accurate Diagnosis
Chung SH et al.

Evaluation of stents by 64MSCT is not recommended in stents with diameters of =2.75mm or stents located at the left circumflex coronary artery.

The diagnostic accuracy of 64MSCT is affected by IQ and strut thickness in assessable stents.

MDLinx:  Feb 23 2010 10:34AM
Matching: coronary restenosis
Find similar documents
HTML
100%
Stentys Drug-Eluting Self-Expanding Coronary Stent Shows 4 Percent Restenosis in Complex Lesions
_ Stentys Drug-Eluting Self-Expanding Coronary Stent Shows 4 Percent Restenosis in Complex Lesions.
TCTMD.com:  Feb 19 2010 2:15AM
Matching: coronary restenosis
Find similar documents
HTML
100%
Medical News: Stentys Drug-Eluting Self-Expanding Coronary Stent Shows 4% Restenosis In Complex Lesions
Medical device pioneer Stentys announced today that the complete 'OPEN-I' clinical study was presented by Stefan Verheye, M.D., Ph.D., at the Joint Interventional Meeting ("JIM") 2010 in Rome, demonstrating superior results in 60 patients (27 Stentys drug...
BioFind:  Feb 16 2010 3:43PM
Matching: coronary restenosis
Find similar documents
HTML
100%
Stentys Drug-Eluting Self-Expanding Coronary Stent Shows 4% Restenosis In Complex Lesions
Medical device pioneer Stentys announced today that the complete 'OPEN-I' clinical study was presented by Stefan Verheye, M.D., Ph.

D., at the Joint Interventional Meeting ('JIM') 2010 in Rome, demonstrating superior results in 60 patients (27 Stentys drug...

Medical News Today:  Feb 16 2010 3:29PM
Matching: coronary restenosis
Find similar documents
HTML
100%
Stentys Drug-Eluting Self-Expanding Coronary Stent Shows 4% Restenosis in Complex Lesions
Medical device pioneer Stentys announced today that the complete OPEN-I clinical study was presented by Stefan Verheye, M.D., Ph.

D., at the Joint Interventional Meeting (JIM) 2010 in Rome, demonstrating superior results in 60 patients (27 Stentys drug...

Genetic Engineering News:  Feb 15 2010 2:56PM
Matching: coronary restenosis
Find similar documents
HTML
62%
Stentys Drug-Eluting Stent Shows 4 Percent Restenosis in Complex Lesions
Medical device pioneer Stentys announced Monday that the complete OPEN-I clinical study was presented by Stefan Verheye, M.D., Ph.D.

Stentys Drug-Eluting Stent Shows 4 Percent Restenosis in Complex Lesions.

FDA News:  Feb 15 2010 10:24PM
Matching: restenosis
Find similar documents
HTML
62%
Sirolimus-Eluting Stent Beneficial for In-Stent Restenosis
_ Sirolimus-Eluting Stent Beneficial for In-Stent Restenosis.
Abstracts in Hematology and Oncology:  Feb 10 2010 12:44AM
Matching: restenosis
Find similar documents
HTML
62%
Sirolimus-Eluting Stent Beneficial for In-Stent Restenosis
_ Sirolimus-Eluting Stent Beneficial for In-Stent Restenosis.
Medscape:  Feb 10 2010 12:11AM
Matching: restenosis
Find similar documents


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.